Larson Financial Group LLC increased its position in shares of Johnson & Johnson (NYSE:JNJ) by 4.0% during the second quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 3,579 shares of the company’s stock after buying an additional 136 shares during the quarter. Larson Financial Group LLC’s holdings in Johnson & Johnson were worth $503,000 at the end of the most recent quarter.
A number of other hedge funds have also recently bought and sold shares of the stock. Austin Private Wealth LLC lifted its stake in Johnson & Johnson by 2.5% in the 1st quarter. Austin Private Wealth LLC now owns 2,830 shares of the company’s stock valued at $371,000 after buying an additional 68 shares in the last quarter. Sun Life Financial INC grew its stake in Johnson & Johnson by 2.5% in the first quarter. Sun Life Financial INC now owns 2,758 shares of the company’s stock worth $362,000 after purchasing an additional 68 shares in the last quarter. Old North State Trust LLC grew its stake in Johnson & Johnson by 0.5% in the second quarter. Old North State Trust LLC now owns 13,666 shares of the company’s stock worth $1,922,000 after purchasing an additional 71 shares in the last quarter. Modus Advisors LLC boosted its position in Johnson & Johnson by 2.0% during the 1st quarter. Modus Advisors LLC now owns 3,666 shares of the company’s stock valued at $481,000 after purchasing an additional 73 shares during the period. Finally, West Oak Capital LLC grew its stake in shares of Johnson & Johnson by 0.4% in the second quarter. West Oak Capital LLC now owns 17,793 shares of the company’s stock worth $2,502,000 after purchasing an additional 75 shares in the last quarter. 68.51% of the stock is currently owned by institutional investors and hedge funds.
A number of equities analysts recently weighed in on JNJ shares. SVB Leerink decreased their price target on Johnson & Johnson from $172.00 to $160.00 and set an “outperform” rating for the company in a research report on Wednesday, April 8th. Argus reaffirmed a “buy” rating and set a $155.00 price target (down from $165.00) on shares of Johnson & Johnson in a research note on Friday, March 27th. Credit Suisse Group restated a “buy” rating and issued a $161.00 price objective on shares of Johnson & Johnson in a research note on Tuesday, April 28th. Bank of America raised shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and boosted their price target for the company from $150.00 to $175.00 in a report on Wednesday, April 22nd. Finally, Citigroup boosted their price target on shares of Johnson & Johnson from $150.00 to $165.00 and gave the company a “buy” rating in a report on Wednesday, April 15th. One analyst has rated the stock with a sell rating, four have issued a hold rating and twelve have assigned a buy rating to the company. Johnson & Johnson presently has an average rating of “Buy” and a consensus target price of $162.93.
Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, April 14th. The company reported $2.30 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.03 by $0.27. Johnson & Johnson had a net margin of 24.47% and a return on equity of 39.71%. The company had revenue of $20.69 billion during the quarter, compared to analyst estimates of $19.48 billion. During the same quarter in the previous year, the business earned $2.10 EPS. The firm’s revenue was up 3.3% on a year-over-year basis. On average, analysts expect that Johnson & Johnson will post 7.7 earnings per share for the current year.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Recommended Story: What defines an oversold asset?
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.